Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) Interest Coverage Ratio: 8.41x

The interest coverage ratio for Bristol-Myers Squibb Company (BMY) is 8.41x as of Wednesday, June 10, 2026.

BMY Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

8.41x

BMY Competitors' Interest Coverage Ratio

NAMEMARKET CAPINTEREST COVERAGE RATIOTTM3Y5Y
Bristol-Myers Squibb Company (BMY)$114.14B8.41xN/AN/AN/A
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B357.95x357.95x174.48x123.56x
CVS Health Corporation (CVS)$125.16B3.33x3.10x3.72x4.16x
Medtronic plc (MDT)$103.04B9.04x8.61x8.24x8.04x
Danaher Corporation (DHR)$130.25B19.38x19.02x23.18x23.65x
Elevance Health Inc. (ELV)$87.43B5.79x6.64x7.93x8.79x
Pfizer Inc. (PFE)$146.36B5.78x5.55x10.96x11.04x
Intuitive Surgical, Inc. (ISRG)$146.44BN/A55.58x55.58x55.58x
Cigna Corporation (CI)$78.25B6.61x6.58x6.49x6.37x
Gilead Sciences, Inc. (GILD)$151.21B11.43x6.56x7.26x7.18x

Financial Health Indicators

Interest Coverage

8.4x

Debt/Equity

2.55

Current Ratio

1.26

Formula: Interest Coverage = EBIT / Interest Expense

Reference ranges:

  • < 1.5x: EBIT is less than 1.5 times interest expense
  • 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
  • 3x - 5x: EBIT is between 3 and 5 times interest expense
  • > 5x: EBIT is more than 5 times interest expense

Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.

Bristol-Myers Squibb Company Interest Coverage Ratio Formula & Definition

Interest Coverage = EBIT / Interest Expense

The interest coverage ratio measures operating earnings relative to interest expense.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company Interest Coverage Ratio FAQ

What is the interest coverage ratio for Bristol-Myers Squibb Company (BMY)?
The interest coverage ratio for BMY stock is 8.41x.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner